247 related articles for article (PubMed ID: 23759003)
1. General practitioner (GP)'s view on screening for prostate cancer in the Netherlands: the impact of a randomized trial.
Schröder FH
BJU Int; 2013 Jul; 112(1):4-5. PubMed ID: 23759003
[No Abstract] [Full Text] [Related]
2. Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners.
Van der Meer S; Kollen BJ; Hirdes WH; Steffens MG; Hoekstra-Weebers JE; Nijman RM; Blanker MH
BJU Int; 2013 Jul; 112(1):26-31. PubMed ID: 23465178
[TBL] [Abstract][Full Text] [Related]
3. [Consensus conference. The detection of localized cancer of the prostate. Paris, 8-9 December 1989].
Ann Urol (Paris); 1990; 24(1):5-8. PubMed ID: 1690964
[No Abstract] [Full Text] [Related]
4. Prostate-specific antigen. Improving its ability to diagnose early prostate cancer.
Oesterling JE
JAMA; 1992 Apr 22-29; 267(16):2236-8. PubMed ID: 1372945
[No Abstract] [Full Text] [Related]
5. Study shows PSA better than DRE in screening for prostate cancer.
Oncology (Williston Park); 1991 Nov; 5(11):36. PubMed ID: 1722420
[No Abstract] [Full Text] [Related]
6. [Prostate-specific antigen in the diagnosis of prostatic carcinoma].
Virseda JA; Morente M; Piris MA; Melchor AM; Gil Pascual B; Gómez A
Actas Urol Esp; 1985; 9(1):89-94. PubMed ID: 2409752
[No Abstract] [Full Text] [Related]
7. Beyond the PSA test: How to better stratify a patient's risk of prostate cancer.
Lewis R; Hornberger B
JAAPA; 2017 Aug; 30(8):51-54. PubMed ID: 28742748
[TBL] [Abstract][Full Text] [Related]
8. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).
Roobol MJ; Schröder FH; van Leenders GL; Hessels D; van den Bergh RC; Wolters T; van Leeuwen PJ
Eur Urol; 2010 Dec; 58(6):893-9. PubMed ID: 20933321
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen and screening for prostate cancer.
Han M; Gann PH; Catalona WJ
Med Clin North Am; 2004 Mar; 88(2):245-65, ix. PubMed ID: 15049577
[TBL] [Abstract][Full Text] [Related]
10. Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.
Braillon A; Dubois G
J Natl Cancer Inst; 2012 May; 104(10):793; author reply 793-4. PubMed ID: 22491229
[No Abstract] [Full Text] [Related]
11. [Current aspects of prostate cancer screening].
Jalón Monzón A; Escaf Barmadah S; Viña Alonso LM; Jalón Monzón M
Semergen; 2017; 43(5):387-393. PubMed ID: 27562331
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
Jackson BR
Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
[No Abstract] [Full Text] [Related]
13. [The detection of cancer of the prostate. Challenge for the 1990s?].
Boccon-Gibod L
Ann Urol (Paris); 1988; 22(6):385-7. PubMed ID: 2464966
[No Abstract] [Full Text] [Related]
14. [Analysis of the serum concentration of prostate-specific antigen as a biological marker in the evolution of disseminated prostatic cancer].
Morote Robles J; de Torres Mateos JA; Soler-Roselló A
Actas Urol Esp; 1988; 12(2):152-7. PubMed ID: 2458015
[No Abstract] [Full Text] [Related]
15. Screening for carcinoma of the prostate with prostate specific antigen.
Muschenheim F; Omarbasha B; Kardjian PM; Mondou EN
Ann Clin Lab Sci; 1991; 21(6):371-80. PubMed ID: 1723583
[TBL] [Abstract][Full Text] [Related]
16. Alternative prostate cancer screening strategies.
Labrecque M; Aprikian A
Ann Intern Med; 2013 May; 158(10):778. PubMed ID: 23689773
[No Abstract] [Full Text] [Related]
17. Alternative prostate cancer screening strategies--in response.
Gulati R; Etzioni R
Ann Intern Med; 2013 May; 158(10):778-9. PubMed ID: 23689774
[No Abstract] [Full Text] [Related]
18. Screening for prostate cancer: an updated review.
Marta GN; Hanna SA; Fernandes da Silva JL; Carvalho Hde A
Expert Rev Anticancer Ther; 2013 Jan; 13(1):101-8. PubMed ID: 23259431
[TBL] [Abstract][Full Text] [Related]
19. Laurence Klotz on the Controversy Surrounding Screening for Prostate Cancer.
Klotz L
Oncology (Williston Park); 2016 Aug; 30(8):694, 764. PubMed ID: 27528237
[No Abstract] [Full Text] [Related]
20. Probability, uncertainty, and prostate cancer.
Concato J
Ann Intern Med; 2013 Feb; 158(3):211-212. PubMed ID: 23381041
[No Abstract] [Full Text] [Related]
[Next] [New Search]
